560 related articles for article (PubMed ID: 34675938)
21. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
22. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
[TBL] [Abstract][Full Text] [Related]
23. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
24. Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease.
Gutiérrez-Hoya A; López-Santiago R; Vela-Ojeda J; Montiel-Cervantes L; Rodríguez-Cortés O; Rosales-García V; Paredes-Cervantes V; Flores-Mejía R; Sandoval-Borrego D; Moreno-Lafont M
J Immunol Res; 2017; 2017():1236219. PubMed ID: 28164135
[TBL] [Abstract][Full Text] [Related]
25. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
26. Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation.
Skert C; Perucca S; Chiarini M; Giustini V; Sottini A; Ghidini C; Martellos S; Cattina F; Rambaldi B; Cancelli V; Malagola M; Turra A; Polverelli N; Bernardi S; Imberti L; Russo D
PLoS One; 2017; 12(4):e0175337. PubMed ID: 28399164
[TBL] [Abstract][Full Text] [Related]
27. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
29. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
30. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease.
Brüggen MC; Klein I; Greinix H; Bauer W; Kuzmina Z; Rabitsch W; Kalhs P; Petzelbauer P; Knobler R; Stingl G; Stary G
Blood; 2014 Jan; 123(2):290-9. PubMed ID: 24255916
[TBL] [Abstract][Full Text] [Related]
31. Correlation of Tc17 cells at early stages after allogeneic hematopoietic stem cell transplantation with acute graft-versus-host disease.
Wang L; Zhao P; Song L; Yan F; Shi C; Li Y; Han M; Lan K
Int Immunopharmacol; 2016 Dec; 41():122-126. PubMed ID: 27846420
[TBL] [Abstract][Full Text] [Related]
32. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
[TBL] [Abstract][Full Text] [Related]
34. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease.
Tanaka J; Imamura M; Kasai M; Hashino S; Kobayashi S; Noto S; Higa T; Sakurada K; Asaka M
Bone Marrow Transplant; 1997 Mar; 19(6):571-6. PubMed ID: 9085737
[TBL] [Abstract][Full Text] [Related]
35. Disturbance in the reconstitution of distinct T-cell subsets and the incidence of GvHD following allo-HSCT in pediatric patients with non-malignant hematological disorders.
Bayegi SN; Hamidieh AA; Behfar M; Bozorgmehr M; Saghazadeh A; Tajik N; Delbandi AA; Zavareh FT; Delavari S; Shekarabi M; Rezaei N
Immunol Lett; 2023 Sep; 261():25-36. PubMed ID: 37474024
[TBL] [Abstract][Full Text] [Related]
36. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
37. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
[TBL] [Abstract][Full Text] [Related]
38. Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-
Song Q; Kong X; Martin PJ; Zeng D
Front Immunol; 2021; 12():700857. PubMed ID: 34539630
[TBL] [Abstract][Full Text] [Related]
39. Targeting the IL17 pathway for the prevention of graft-versus-host disease.
van der Waart AB; van der Velden WJ; Blijlevens NM; Dolstra H
Biol Blood Marrow Transplant; 2014 Jun; 20(6):752-9. PubMed ID: 24565991
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
